Astellas sells US production site to APP
This article was originally published in Scrip
Astellashas sold a US manufacturing facility in Grand Island, New York, toAPP Pharmaceuticals. The move forms part of a wider reduction in production facilities under Astellas's current mid-term business plan, which calls for cutting the number of these to around 10 worldwide by April 2011. The Japanese firm will continue to lease the facility from APP until next spring, when it will transfer the production of the atopic dermatitis product Protopic (topical tacrolimus) from there to its Toyama plant in Japan. APP, a US firm specialising in generic injectables, already has operations on Grand Island and will offer employment to most of the 90 or so employees at the former Astellas facility.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.